How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity
Tumor necrosis factor (TNF) α inhibitors are the most commonly used agents to treat rheumatoid arthritis (RA) and other inflammatory arthropathies. Five drugs belonging to the family of TNFα inhibitors have been certified in Russia for treating RA: infliximab (INF), adali- mumab (ADA), golimumab, ce...
Saved in:
| Main Author: | D.E. Karateev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2014-05-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/548 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of tumor necrosis factor-α inhibitors in the treatment of various immunoinflammatory diseases: focus on immunogenicity
by: T. Yu. Nuriahmetova, et al.
Published: (2023-08-01) -
Golimumab in the treatment of inflammatory diseases: A role of immunogenicity
by: D. E. Karateev
Published: (2016-01-01) -
The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01) -
Ihmor necrosis factor-a inhibitors and cardiovascular risk in rheumatoid arthritis
by: Tatiana Valentinovna Popkova, et al.
Published: (2012-12-01) -
Choice of therapeutic tactics after failure of the first tumor necrosis factor-α inhibitor
by: N. V. Chichasova
Published: (2017-09-01)